Characteristics of patients with chronic spontaneous urticaria who are late-responders to omalizumab

J Allergy Clin Immunol Pract. 2024 Sep;12(9):2537-2539. doi: 10.1016/j.jaip.2024.05.043. Epub 2024 Jun 1.

Authors

Giselle Mosnaim¹, Thomas B Casale², Michael Holden³, Benjamin Trzaskoma³, Jonathan A Bernstein⁴

Affiliations

¹ Department of Medicine, Endeavor Health, Glenview, Ill. Electronic address: [email protected].
² Division of Allergy and Immunology, University of South Florida, Tampa, Fla.
³ Genentech, Inc., South San Francisco, Calif.
⁴ College of Medicine, University of Cincinnati, Cincinnati, Ohio.

PMID: 38830576
DOI: 10.1016/j.jaip.2024.05.043

No abstract available

Publication types

Letter

MeSH terms

Adult
Anti-Allergic Agents* / therapeutic use
Chronic Urticaria* / drug therapy
Female
Humans
Immunoglobulin E / blood
Male
Middle Aged
Omalizumab* / therapeutic use
Treatment Outcome

Substances

Omalizumab
Anti-Allergic Agents
Immunoglobulin E